Trastuzumab Deruxtecan Increases Survival in HER2-low Metastatic Breast Cancer

In this interview, Dr. Shanu Modi – Professor of Medicine at Memorial Sloan Kettering Cancer Center, talked with the Oncology Brothers (Drs. Rohit and Rahul Gosain) about the DESTINY-Breast04 study, of which Dr. Modi was the lead investigator. This important analysis found that the treatment trastuzumab deruxtecan yields notably longer progression-free and overall survival in patients with HER2-low metastatic breast cancer – an encouraging result considering that currently available HER2-directed therapies have been largely ineffective in this patient population.